Company
Headquarters: Lianyungang, China
Employees: 28,903
CN¥284.76 Billion
CNY as of Jan. 1, 2025
US$39.01 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
| Merck | $244.44 B |
| Roche | $219.35 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥26.00 B |
| EBITDA | CN¥6.04 B |
| Gross Profit TTM | CN¥22.26 B |
| Profit Margin | 20.96% |
| Operating Margin | 21.51% |
| Quarterly Revenue Growth | 12.70% |
Jiangsu Hengrui Medicine Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600276 wb_incandescent